Clinical trial
Biological Markers of Response to Treatment in Major Depressive Disorder
NCT00361218 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00361218 |
|---|---|
| Title | Biological Markers of Response to Treatment in Major Depressive Disorder |
| Official title | Serum Brain-Derived Neurotrophic Factor (BDNF) and QEEG as Biological Markers of Response to (Es)Citalopram Treatment in Major Depressive Disorder |
| Lead sponsor | Massachusetts General Hospital, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | open-label selective serotonin reuptake inhibitor (SSRI) |
| Enrollment | 72 |
| Start date | Oct 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Aug 8, 2006 |
| Last update posted | May 11, 2018 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: